In order to assess the safety and efficacy of the newly emerging non-adhesive embolic agent, PHIL (Precipitating Hydrophobic Injectable Liquid), we conducted a retrospective monocentric study using a prospectively accumulated database of patients that used this innovation in treating brain arteriovenous malformations or dural arteriovenous fistulas. After gathering the data from this small population of patients via paper case reports developed specifically for evaluation, we considered the socio-demographic data, medical history, brain arteriovenous malformation morphology, procedure details, complications, and immediate follow up clinical angiographic results. In inspecting these factors and other statistical data, we were able to observe the rate of complete occlusion in both dural arteriovenous fistula and brain arteriovenous malformation patients and presurgical volume reduction of the nidus in brain arteriovenous malformation patients.